Tirzepatide after bariatric surgery

A real-world Italian study published in Obesity Surgery on 5 June 2026 followed 34 patients who had regained weight after bariatric surgery and were then treated with tirzepatide. After 24 weeks, participants lost a mean 18.1% of total body weight, with no treatment discontinuations due to side effects^[1]. The finding adds to a small but growing body of evidence that GLP-1 class drugs can serve as a pharmacological backstop when surgical weight loss stalls or reverses.

The study and its numbers

Vinciguerra and colleagues at the University of Catania enrolled 34 adults (26 female, 8 male) who had experienced recurrent weight gain after a prior bariatric procedure (32 patients) or endoscopic bariatric therapy (2 patients). All received once-weekly subcutaneous tirzepatide at doses ranging from 2.5 to 10 mg. At 24 weeks, mean total body weight loss was 18.1% (standard deviation 5.6%, p < 0.0001), waist circumference dropped significantly (p < 0.0001), and most participants moved from obese to overweight or normal BMI categories^[1].

Adverse events were exclusively gastrointestinal: constipation, diarrhoea, and nausea, all generally mild. No patient stopped treatment because of side effects^[1]. That tolerability profile is consistent with the larger tirzepatide trial programme, where GI symptoms are the dominant adverse event class and are mostly dose-dependent and transient during titration. The Mounjaro prescribing information^[4] lists nausea, diarrhoea, decreased appetite, vomiting, and constipation as the five most common adverse reactions across the SURPASS and SURMOUNT programmes.

Why weight regain after surgery matters

Bariatric surgery remains the most effective single intervention for severe obesity, but weight regain is common. Between 20% and 35% of patients regain clinically meaningful weight within five years of their procedure. The reasons are mixed: hormonal adaptation, behavioural drift, anatomical changes, and the same biological defence of higher body weight that drove the original obesity. Until recently, the main response to post-surgical regain was revisional surgery, a second operation that carries its own risks and is not always feasible.

The clinical conversation has shifted because GLP-1 receptor agonists give clinicians a pharmacological option that did not exist at scale five years ago. For patients who have already undergone sleeve gastrectomy or Roux-en-Y gastric bypass and are now regaining, the question is whether drugs originally tested in a non-surgical population also work in a post-surgical body. The gut anatomy is different. Gastric emptying is already altered. Nutrient absorption is changed. These are not trivial physiological differences, and they mean that results from the general SURMOUNT programme cannot simply be assumed to transfer.

A 2025 systematic review and meta-analysis of 19 studies found that GLP-1 receptor agonists used as adjuncts to bariatric surgery produced significant weight and BMI reductions, with tirzepatide outperforming semaglutide over six months^[2]. The authors described these drugs as "a promising alternative to revisional surgery," though they noted the need for longer-term randomised trials.

What this study does not settle

The Vinciguerra study is observational, not randomised, and the sample is small (n = 34). There is no control group, so the 18.1% figure cannot be attributed to tirzepatide alone versus dietary counselling, increased clinical attention, or regression to the mean. The follow-up is 24 weeks. We do not know what happens at one year or two years, and the SURMOUNT-4 discontinuation data showed substantial weight regain when tirzepatide was stopped in the general obesity population^[3]. Whether the same pattern holds in post-bariatric patients is an open question.

The study also does not address cost, insurance coverage, or how long therapy should continue. If post-bariatric tirzepatide use follows the same chronic-therapy model that the broader obesity trials imply, the practical and financial questions will be substantial. Branded Mounjaro and Zepbound are expensive, and reimbursement criteria vary by country and indication. In the UK, for example, NICE technology appraisal TA1026 covers tirzepatide for obesity management within specialist weight-management services, but post-bariatric use sits outside that pathway.

Where this fits

For readers following the tirzepatide evidence base, this paper fills a gap. The large Phase 3 SURMOUNT trials enrolled patients with primary obesity, not post-surgical regain. The post-bariatric population has different physiology (altered gut anatomy, changed hormonal signalling) and different clinical expectations. Early real-world data like this helps clinicians and patients understand whether the drug works in that specific context, even if it cannot yet tell us how well or for how long.

The broader trend is clear. As semaglutide and tirzepatide move from clinical trials into routine practice, clinicians are testing them in populations the original pivotal studies did not cover. Post-bariatric patients are one such group. The Vinciguerra paper is a single observational study from one centre in Italy. It is not the final word. But for patients and clinicians weighing the options after weight regain, it is one of the first data points specific to their situation.

The prescribing information for Mounjaro^[4] does not list post-bariatric weight regain as a labelled indication. Any use in this setting is off-label, and decisions about starting, adjusting, or stopping treatment belong with the surgical and medical team managing the individual patient.